Ambey Laboratories Q4 FY26 Results: Net Profit ₹2 Cr, Up 122.2% QoQ
Ambey Laboratories Limited reported revenue from operations of ₹40.5 Cr and net profit of ₹2 Cr for Q4 FY26.
- Key figure
- Net profit ₹2 Cr
ALFA Filings
Every announcement, straight from the exchange
Announcement type
Time
8 announcements with these filters
Ambey Laboratories Limited reported revenue from operations of ₹40.5 Cr and net profit of ₹2 Cr for Q4 FY26.
Ambey Laboratories Limited approved its audited FY26 financial results, reporting consolidated revenue of ₹141.54 Crore. The board also reviewed fund utilization and related party disclosures.
Dhansa Labs Limited submitted its annual SDD Compliance Certificate for the financial year 2026. This confirms regulatory adherence to SEBI insider trading monitoring requirements.
Ambey Laboratories Limited will change its name to Dhansa Labs Limited and its NSE symbol to DHANSA. The change is effective from June 01, 2026.
Dhansa Labs Limited allotted 3,63,043 equity shares following warrant conversions, raising ₹1.67 Crore. This exercise increases the company's paid-up capital and strengthens its equity base.
Ambey Laboratories scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The company's trading window remains closed until May 31, 2026.
Dhansa Labs Limited submitted a missing Chartered Accountant's Certificate regarding its postal ballot process. The certificate confirms compliance with rebranding regulations for its name change.
Ambey Laboratories approved converting a ₹9.10 Crore inter-company loan into equity shares of its subsidiary. The restructuring strengthens the subsidiary's capital base without fresh cash outflow.